Report of Foreign Issuer (6-k)
30 May 2018 - 6:03AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under
the Securities Exchange Act of 1934
For
the Month of May 2018
001-37353
(Commission
File Number)
BIONDVAX
PHARMACEUTICALS LTD.
(Exact
name of Registrant as specified in its charter)
14
Einstein St.
Ness
Ziona
Israel
7414002
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
____
Indicate
by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If
“Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-N/A
Financial
Statements for the period ending on March 31, 2018
On
May 29, 2018, BiondVax Pharmaceuticals Ltd. (“BiondVax”) issued a press release announcing its financial results for
the period ended March 31, 2018. A copy of this press release and interim unaudited financial statements for period ended
March 31, 2018, are attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and are incorporated herein by reference.
Compensation
to Audit Committee members
On
May 28, 2018, the compensation committee and the board of directors approved and ratified the compensation to all members of the
audit and compensation committees, Ms. Michal Marom Brikman, Dr. Ruth Ben Yakar and Dr. Morris Laster, in accordance with the
Israeli Companies Law (Rules Regarding Compensation and Expenses to External Director)- 2000-5760. Accordingly, Ms. Brikman, Dr.
Ben Yakar and Dr. Laster shall be entitled to receive the minimum annual and participatory compensation, equal to NIS 21,425 per
year and NIS 620 per meeting, respectively.
Exhibit
Index
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
BiondVax
Pharmaceuticals Ltd.
|
|
|
|
Date:
May 29, 2018
|
By:
|
/s/
Ron Babecoff
|
|
|
Ron
Babecoff
|
|
|
Chief
Executive Officer
|
2
BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
From Apr 2024 to May 2024
BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
From May 2023 to May 2024